Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials

Tang, Hung‐Jen; Weng, Teng-Song; Chen, Yu-Hung; Chao, Chien‐Ming

doi:10.1016/j.jmii.2022.08.005

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding safety issues associated with the use of Jakinibs, Chen et al ( 2021) and Kramer et al (2022), in two different meta-analyses, did not find any association between the use of jakinib and a higher risk of adverse events of any grade and secondary infections in COVID-19 patients compared to the control groups. In a recent pooled analysis of seven randomized controlled trials, Jakinib in the treatment group significantly reduced the all-cause 28-day mortality rate (31%) and risk of 14-day mortality (35%) than the control group (Tang et al, 2022). Also, both Jakinibs and COVID-19 are linked with potential thrombotic complications of their own, but to date, there is no existing evidence suggesting increased thrombotic risk associated with Jakinibs use in treating COVID-19 (Levy et al, 2022).…”

Section: Limitationsmentioning

confidence: 99%

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

et al. 2023

View full text Add to dashboard Cite

Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been implicated in immunopathogenesis of COVID-19 infection under different stages such as viral entry, escaping innate immunity, replication, and subsequent inflammatory processes. Prompted by this fact and prior utilization as an immunomodulatory agent for several autoimmune, allergic, and inflammatory conditions, Jakinibs have been recognized as validated small molecules targeting the rapid release of proinflammatory cytokines, primarily IL-6, and GM-CSF. Various clinical trials are under investigation to evaluate Jakinibs as potential candidates for treating COVID-19. Till date, there is only one small molecule Jakinib known as baricitinib has received FDA-approval as a standalone immunomodulatory agent in treating critical COVID-19 patients. Though various meta-analyses have confirmed and validated the safety and efficacy of Jakinibs, further studies are required to understand the elaborated pathogenesis of COVID-19, duration of Jakinib treatment, and assess the combination therapeutic strategies. In this review, we highlighted JAK-STAT signalling in the pathogenesis of COVID-19 and clinically approved Jakinibs. Moreover, this review described substantially the promising use of Jakinibs and discussed their limitations in the context of COVID-19 therapy. Hence, this review article provides a concise, yet significant insight into the therapeutic implications of Jakinibs as potential anti-COVID agents which opens up a new horizon in the treatment of COVID-19, effectively.

show abstract

Section: Limitationsmentioning

confidence: 99%